Review journal"Penetration" We are happy to offer state-of-the-art commentaries on levofloxacin including Special Interviews with world-recognized experts as well as summaries of Review Articles on a variety of research areas of current interest, from our annual periodical, Penetration. Review High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Andrew F. Shorr, 2007: 13-18  NEW Levofloxacin for the Treatment of Urosepsis Ercole Concia, Anna Maria Azzini 2007: 19-24  NEW Resistance Challenges Threatening the Treatment of Pseudomonas aeruginosa Infections with Levofloxacin: The Role of a Levofloxacin-Imipenem Combination for Prevention of Resistance Philip D. Lister, Daniel J. Wolter 2007: 25-35  NEW Successful Treatment of Helicobacter pylori Infections with Levofloxacin: A Case Report from Taiwan and a Review of the Literature Jaw-Town Lin 2007: 36-40  NEW Levofloxacin: Today's Choice for the Treatment of Typhoid Fever? An Illustrative Case Report from Indonesia R. H. H. Nelwan 2007: 41-44  NEW Antimicrobial Susceptibility among Streptococcus pneumoniae: Data from the GLOBAL Study 2005/2006 Mark E. Jones, Nina P. Brown, Deborah C. Draghi, Clyde Thornsberry, Daniel F. Sahm. 2007: 15-22 Using Safety Profiles to Differentiate between the Newer Fluoroquinolones Keith A. Rodvold. 2007: 23-30 Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis: Position in Recent Guidelines Hartmut M Lode. 2006: 21-27 Antimicrobial Chemotherapy for Legionnaires’ Disease: Levofloxacin Versus Macrolides Rosa Ma Blázquez Garrido. 2006: 28-33 Clinical Safety Profile of Fluoroquinolones Keith A Rodvold. 2006: 34-43 Levofloxacin for the Treatment of Respiratory Tract Infections Based on Treatment Guidelines Chi-Huei Chiang. 2006: 44-51 Levofloxacin for the Treatment of Community-Acquired Pneumonia in the US Based on the Latest Treatment Guidelines John G Bartlett. 2005: 15-20 The Experience of Using Levofloxacin in the Emergency Department Sheng-Chuan Hu. 2005: 21-25 Clinical Usefulness of Levofloxacin for the Treatment of Urinary Tract Infections Kurt G. Naber, Florian M. E. Wagenlehner. 2005: 26-32 The Diagnosis, Treatment and Management of Typhoid Fever and the Role of Fluoroquinolones R.H.H. Nelwan. 2005: 33-38 Levofloxacin in the Treatment of Multi-Drug Resistant Streptococcus pneumoniae Burke A. Cunha. 2005: 39-46 Role of Levofloxacin in the Treatment of Community-Acquired Pneumonia in Taiwan:In Vitro Activity and Clinical Efficacy Po-Ren Hsueh 2004: 24-28 Early Switch Therapy from Intravenous to Oral Levofloxacin Versus Intravenous Ceftriaxone to Oral Cefuroxime Axetil in the Treatment of Moderate to Severe Community-Acquired Pneumonia Hadiarto Manggunnegoro, Wahyuningsih Soeharno, Adria Rusli 2004: 29-35 Levofloxacin in the Treatment of Respiratory Tract Infections Due to Atypical Pathogens Blasi F. Cosentini R. Tarsia P. 2003: 47-52 Levofloxacin in the Management of Lower Respiratory Tract Infections due to Typical Pathogens Habib MP. 2003: 40-46 Use of Levofloxacin in the Treatment of Respiratory Tract Infections in an Era of Increasing Resistance: A Review of International Surveillance and TRUST Data Jones ME. Thornsberry C. Karlowsky JA. Sahm DF. 2003: 33-40 An Overview: Appropriate Applications of PO and IV Therapy with Levofloxacin for Patients with Lower Respiratory Tract Infections Fogarty CM. 2002: 29-36 Clinical efficacy and safety of levofloxacin for mild to moderate community-acquired pneumonia Carbon C. 2002: 37-41 Levofloxacin for the Treatment of Severe Community-Acquired Pneumonia Patients with Risk Factors for Complications (Bacteremia and/or Sepsis) Veyssier P. 2002: 42-48 Clinical Utilities of Sequential Therapy (Step-Down from Intravenous to Oral) with Levofloxacin for Hospitalized Patients with Lower Respiratory Tract Infections Norby SR. 2001: 38-42 Levofloxacin for the Management of Patients with Community-Acquired Pneumonia: A Comparison of Bed Days per Patient Managed with Conventional Regimens Marrie TJ. 2001: 43-47 Position of Levofloxacin in the Management of Bronchitis and Bronchiolitis Shah PM. 2000: 22-26 New Strategies for the Management of Community-Acquired Pneumonia Carbon C. 2000: 27-31 New Strategies for the Management of Legionnaires' Disease Cunha BA. 2000: 32-39 New Strategies for the Management of Cystic Fibrosis and Bronchiectasis Masterton RG. 2000: 40-46 New Strategies for the Management of Sinusitis Adelglass J. 2000:47-51 In Vitro Activity of Levofloxacin against Penicillin-Resistant Streptococcus pneumoniae Hu BS. 1999: 29-32 The Clinical Pharmacokinetics of Levofloxacin Fish DN. 1999: 33-39 Drug-Drug Interactions Associated with Levofloxacin Chow AT. Chien SC. 1999: 40-48 Levofloxacin in the Treatment of Community-Acquired Pneumonia File TM. 1998: 26-30 Clinical Use of Levofloxacin for Intractable RTI in Outpatients Kobayahshi H. 1998: 31-35 Clinical Efficacy of Levofloxacin in Skin and Soft Tissue Infection Nicodemo A. 1998: 36-37 In Vitro and In Vivo Antimicrobial Activity of Levofloxacin. Morrissey I. 1996: 41-45. Special Interview The Role of Levofloxacin in Treating Urinary Tract Infections Richard GA. 2002: 5-16 Levofloxacin and Its Effective Use against RTI-Related Resistant Pathogens Thornsberry C. 1999: 5-12. A Comparison of Clinical Outcomes Using Levofloxacin versus ß-lactams and Macrolides in Respiratory Tract Infections Smith RP. 1999: 18-23. Levofloxacin - The "Respiratory Fluoroquinolone" DeAbate CA. 1998: 5-10. Levofloxacin in the Treatment of Community-Acquired Pneumonia. Fogarty CM. 1997: 5-9. Levofloxacin - An Extremely Useful Drug in the Treatment of Sinusitis. Sydnor TA. 1997: 16-20. Levofloxacin: Therapeutic Advances in the Treatment of Severe Infections. Norrby SR. 1996: 5-10. Special Message for the 21st Century A Decade of Change and Future Possibilities Rubinstein E. 2001: 5-6. ©1998-2005 BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited. Disclaimer